Published in AIDS Res Hum Retroviruses on July 19, 2013
Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women | NCT00326716
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther (2015) 0.97
Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir. Infect Dis Obstet Gynecol (2016) 0.75
Antenatal atazanavir: a retrospective analysis of pregnancies exposed to atazanavir. Infect Dis Obstet Gynecol (2014) 0.75
Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics (2004) 10.36
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr (2010) 2.64
Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1. Clin Infect Dis (2005) 1.33
Phototherapy use in jaundiced newborns in a large managed care organization: do clinicians adhere to the guideline? Pediatrics (2003) 1.31
Hyperbilirubinemia in the term newborn. Am Fam Physician (2002) 1.30
Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr (2011) 1.24
Atazanavir: a review of its use in the management of HIV-1 infection. Drugs (2009) 1.21
BCRP/ABCG2 in the placenta: expression, function and regulation. Pharm Res (2008) 1.17
Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women. HIV Med (2011) 1.01
Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia. Eur J Obstet Gynecol Reprod Biol (2011) 1.00
Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS (2007) 0.99
Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol (2011) 0.98
Molecular bases of the fetal liver-placenta-maternal liver excretory pathway for cholephilic compounds. Liver Int (2008) 0.86
Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil. AIDS Res Hum Retroviruses (2012) 0.84
Hyperbilirubinemia. Crit Care Nurs Clin North Am (2009) 0.80
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis (2011) 5.94
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet (2010) 5.41
Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med (2010) 3.14
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr (2010) 2.64
Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol (2006) 2.27
Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa. AIDS (2010) 2.13
Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2003) 1.92
Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study. PLoS One (2010) 1.83
Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol (2010) 1.76
Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med (2010) 1.71
Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr (2008) 1.57
Risk factors for in utero and intrapartum transmission of HIV. J Acquir Immune Defic Syndr (2005) 1.57
Integration of antiretroviral treatment within antenatal care in Gauteng Province, South Africa. J Acquir Immune Defic Syndr (2006) 1.55
Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J Clin Pharmacol (2005) 1.50
Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis (2004) 1.48
Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother (2004) 1.35
Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis (2009) 1.30
Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety (2010) 1.24
Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda. Clin Infect Dis (2003) 1.20
Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J Infect Dis (2012) 1.18
The relationship of pregnancy to human immunodeficiency virus disease progression. Am J Obstet Gynecol (2003) 1.13
A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results. HIV Clin Trials (2012) 1.13
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther (2013) 1.12
Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol (2009) 1.11
Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr (2009) 1.11
First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial. AIDS (2011) 1.10
The HVTN protocol 903 vaccine preparedness study: lessons learned in preparation for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr (2008) 1.08
The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women. Antivir Ther (2011) 1.05
A multifaceted mentoring model for minority researchers to address HIV health disparities. Am J Public Health (2009) 1.01
Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study. AIDS Patient Care STDS (2012) 1.00
Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother (2007) 0.98
Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. J Antimicrob Chemother (2010) 0.96
Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther (2011) 0.94
Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. J Acquir Immune Defic Syndr (2003) 0.93
Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J Acquir Immune Defic Syndr (2009) 0.93
Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects. J Clin Pharmacol (2010) 0.92
Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis. Chem Res Toxicol (2011) 0.90
Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir. Antimicrob Agents Chemother (2004) 0.90
The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. Antivir Ther (2011) 0.89
Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study. Clin Infect Dis (2009) 0.89
Prolonged deferral of antiretroviral therapy in the SAPIT trial: did we need a clinical trial to tell us that this would increase mortality? S Afr Med J (2010) 0.87
Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate. Antivir Ther (2013) 0.87
Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment. Antivir Ther (2015) 0.86
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects. Clin Pharmacokinet (2012) 0.86
Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study. AIDS Care (2010) 0.86
96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients. J Int Assoc Physicians AIDS Care (Chic) (2010) 0.86
Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals. Antivir Ther (2010) 0.85
The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus. Clin Drug Investig (2014) 0.85
Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother (2012) 0.85
Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study. J Acquir Immune Defic Syndr (2016) 0.84
Changes in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patients with HIV-1 infection: the CASTLE body composition substudy. J Acquir Immune Defic Syndr (2015) 0.84
Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir. J Acquir Immune Defic Syndr (2003) 0.84
Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients. Antimicrob Agents Chemother (2011) 0.83
Relationship of pregnancy to human papillomavirus among human immunodeficiency virus-infected women. Obstet Gynecol (2006) 0.83
Atazanavir pharmacokinetics, efficacy and safety in pregnancy: a systematic review. Antivir Ther (2012) 0.83
Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther (2011) 0.83
Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve. Pharmacotherapy (2013) 0.83
Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. J Antimicrob Chemother (2011) 0.83
Pharmacodynamics of selective inhibition of γ-secretase by avagacestat. J Pharmacol Exp Ther (2012) 0.83
Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women. J Acquir Immune Defic Syndr (2016) 0.83
Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks. AIDS Patient Care STDS (2011) 0.82
Recruitment of Caribbean female commercial sex workers at high risk of HIV infection. Rev Panam Salud Publica (2013) 0.82
Building capacity for the assessment of HIV drug resistance: experiences from the PharmAccess African Studies to Evaluate Resistance network. Clin Infect Dis (2012) 0.81
Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men. Clin Drug Investig (2012) 0.81
Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study. J Antimicrob Chemother (2011) 0.81
Changing trends in clinical AIDS presentations and survival among HIV-1-infected women. J Womens Health (Larchmt) (2004) 0.81
Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects. J Acquir Immune Defic Syndr (2013) 0.81
Posttraumatic stress disorder symptoms and adherence among women living with HIV. Ethn Dis (2005) 0.80
Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients. AIDS Patient Care STDS (2011) 0.80
Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient. AIDS (2004) 0.80
Mode of delivery and postpartum HIV-1 disease progression: the Women and Infants Transmission Study. AIDS (2006) 0.79
Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection. Clin Drug Investig (2014) 0.78
Concerns about HIV and sexually transmitted infection among low-risk and high-risk women, Puerto Rico. Ethn Dis (2008) 0.76
A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents. Antivir Ther (2014) 0.76
Development and field testing of an HIV medication touch screen computer patient adherence tool with telephone-based, targeted adherence counseling. J Int Assoc Provid AIDS Care (2012) 0.76
The medical proof doesn't get much better than VMMC. S Afr Med J (2012) 0.75
No association between antepartum serologic and genital tract evidence of herpes simplex virus-2 coinfection and perinatal HIV-1 transmission. Am J Obstet Gynecol (2008) 0.75
Electrocardiographic changes in HIV-infected, drug experienced patients treated with atazanavir. AIDS (2008) 0.75
A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat. Br J Clin Pharmacol (2013) 0.75
A call to action: Addressing the reproductive health needs of women with drug-resistant tuberculosis. S Afr Med J (2016) 0.75
Further information on the administration of h2-receptor antagonists with atazanavir. J Acquir Immune Defic Syndr (2006) 0.75
Changes in biomarkers in HIV-1-infected treatment-naive patients treated with tenofovir DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ritonavir for 96 weeks: the CASTLE biomarker substudy. Antivir Ther (2014) 0.75